Eli Lilly and Peptron entered a non-binding Platform Technology Evaluation Agreement in October 2024 granting Lilly only a limited, non-exclusive license for internal R&D on applying the SmartDepot ultrasonic spray-dried PLGA microsphere platform to select peptides. The original 14-month term was extended to a maximum of 24 months ending October 7, 2026, explicitly framing any future commercial license or technology transfer as a separate, uncommitted step. No binding commercial agreement has been announced despite nearly two years of joint evaluation, recent expansion into CNS applications, and preclinical data sharing on candidates like PT403. Lilly retains unilateral termination rights with 30 days’ notice and has pursued alternative long-acting delivery partnerships elsewhere. With weeks remaining before the deadline and no reported progress toward definitive terms, trader consensus strongly favors resolution to “No.”
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% вероятность
$11,314 Объем
$11,314 Объем
6 окт. 2026 г.
13% вероятность
$11,314 Объем
$11,314 Объем
6 окт. 2026 г.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron entered a non-binding Platform Technology Evaluation Agreement in October 2024 granting Lilly only a limited, non-exclusive license for internal R&D on applying the SmartDepot ultrasonic spray-dried PLGA microsphere platform to select peptides. The original 14-month term was extended to a maximum of 24 months ending October 7, 2026, explicitly framing any future commercial license or technology transfer as a separate, uncommitted step. No binding commercial agreement has been announced despite nearly two years of joint evaluation, recent expansion into CNS applications, and preclinical data sharing on candidates like PT403. Lilly retains unilateral termination rights with 30 days’ notice and has pursued alternative long-acting delivery partnerships elsewhere. With weeks remaining before the deadline and no reported progress toward definitive terms, trader consensus strongly favors resolution to “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Открытие рынка: May 5, 2026, 8:02 PM ET
Объем
$11,314Дата окончания
7 окт. 2026 г.Открытие рынка
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron entered a non-binding Platform Technology Evaluation Agreement in October 2024 granting Lilly only a limited, non-exclusive license for internal R&D on applying the SmartDepot ultrasonic spray-dried PLGA microsphere platform to select peptides. The original 14-month term was extended to a maximum of 24 months ending October 7, 2026, explicitly framing any future commercial license or technology transfer as a separate, uncommitted step. No binding commercial agreement has been announced despite nearly two years of joint evaluation, recent expansion into CNS applications, and preclinical data sharing on candidates like PT403. Lilly retains unilateral termination rights with 30 days’ notice and has pursued alternative long-acting delivery partnerships elsewhere. With weeks remaining before the deadline and no reported progress toward definitive terms, trader consensus strongly favors resolution to “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Объем
$11,314Дата окончания
7 окт. 2026 г.Открытие рынка
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly and Peptron entered a non-binding Platform Technology Evaluation Agreement in October 2024 granting Lilly only a limited, non-exclusive license for internal R&D on applying the SmartDepot ultrasonic spray-dried PLGA microsphere platform to select peptides. The original 14-month term was extended to a maximum of 24 months ending October 7, 2026, explicitly framing any future commercial license or technology transfer as a separate, uncommitted step. No binding commercial agreement has been announced despite nearly two years of joint evaluation, recent expansion into CNS applications, and preclinical data sharing on candidates like PT403. Lilly retains unilateral termination rights with 30 days’ notice and has pursued alternative long-acting delivery partnerships elsewhere. With weeks remaining before the deadline and no reported progress toward definitive terms, trader consensus strongly favors resolution to “No.”
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы